Stock AKYA AKOYA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Akoya Biosciences, Inc.

Equities

AKYA

US00974H1041

Real-time Estimate Cboe BZX
Other stock markets
 09:48:03 2024-04-26 am EDT 		5-day change 1st Jan Change
3.845 USD +0.65% Intraday chart for Akoya Biosciences, Inc. 0.00% -22.13%
Apr. 05 Akoya Biosciences Showcases Spatial Biology 2.0 Solutions At AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale CI
Mar. 06 JPMorgan Adjusts Price Target on Akoya Biosciences to $10 From $12, Maintains Overweight Rating MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
AKOYA BIOSCIENCES, INC. Stock Akoya Biosciences, Inc.
-22.13% 189M -
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+7.14% 218B
B
DANAHER CORPORATION Stock Danaher Corporation
+5.33% 182B
B-
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+10.03% 132B
B-
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.75% 108B
A-
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.44% 52.98B
B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-1.89% 47.59B
B+
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-2.88% 39.96B
A
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+10.59% 39.22B -
RESMED, INC. Stock ResMed, Inc.
+18.02% 26.94B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. AKYA Stock
  4. Ratings Akoya Biosciences, Inc.